BNP Paribas Asset Management
CGEM icon

BNP Paribas Asset Management’s Cullinan Oncology CGEM Stock Holding History

BNP Paribas Asset Management’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.4K Sell
683
-239
-26% -$3.55K ﹤0.01% 2165
2026
Q1 		$13.1K Buy
+922
New +$11.8K ﹤0.01% 2146

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

BNP Paribas Asset Management's CGEM Position: Q2 2026 in Review

BNP Paribas Asset Management reduced its Cullinan Oncology (CGEM) stake by 26% in Q2 2026, selling an estimated $3.55K and leaving 683 shares worth $12.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2165.

BNP Paribas Asset Management first reported a position in CGEM in Q1 2026 and has held it in 2 quarters since. The position peaked at $13.1K in Q1 2026. 183 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • BNP Paribas Asset Management held 683 shares of Cullinan Oncology worth $12.4K as of Q2 2026.
  • BNP Paribas Asset Management sold 239 Cullinan Oncology shares in Q2 2026, an estimated $3.55K.
  • Cullinan Oncology made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #2165 holding.
  • BNP Paribas Asset Management first reported a position in Cullinan Oncology in Q1 2026 and has held it in 2 quarters since.
  • BNP Paribas Asset Management's Cullinan Oncology position peaked at $13.1K in Q1 2026.
  • 183 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.